Atrium appoints Mario Paradis as Vice President and Chief Financial Officer



    The Company has also strengthened its sales and marketing team with two
    new appointments to complement its resources in the United States and in
    Europe

    QUEBEC CITY, Feb. 29 /CNW Telbec/ - Mr. Pierre Fitzgibbon, President and
Chief Executive Officer of Atrium Innovations Inc. (TSX: ATB), is pleased to
announce the appointment of Mr. Mario Paradis, CA, to the position of Vice
President and Chief Financial Officer of the Company. Mr Paradis will begin
his new duties in early April and is succeeding Mr. John Dempsey, who will
contribute during the transition as a consultant to the company.
    Previously for a period of 9 years, Mr. Paradis held positions with
different levels of responsibilities at AEterna Zentaris. He acted as Director
of Finance and Vice President, Finance and Administration for a period of
8 years and was the Corporate Secretary for the last 4 years. In May 2007, he
was named Senior Vice President, Administration and Legal Affairs and was a
key strategic executive to the CEO and executive management team in developing
long term strategy, including M&A transactions. Prior to joining AEterna
Zentaris, Mr. Paradis worked for 11 years with PricewaterhouseCoopers where he
successively held positions in audit, tax and finally in certification as
Senior Director.
    "Mario Paradis brings the Company solid expertise in financial operations
management, strategy and finance in the health industry. These qualities
perfectly meet the present and future needs of Atrium, which is a rapidly
growing company that is pursuing a dynamic acquisitions program requiring
solid integration capabilities. We are very happy to welcome Mr. Paradis to
the Atrium team. I would also like to thank John for his valuable contribution
to Atrium's development in recent years, particularly in the preparation of
Atrium's initial public offering in 2005. We are also pleased to know that we
can benefit from his expertise during the transition period in his role as a
consultant to the Company's executive team. One of John's tasks will be to
assist the Company with the divestiture of its AI & SC Division," underlined
Mr. Fitzgibbon.

    Sales and Marketing team appointments

    Furthermore, Atrium has recruited two high-calibre individuals in sales
and marketing to support its business development plan in Europe and the
United States.
    Mr. René Augstburger has been appointed Marketing Vice President, Europe.
In this new role, Mr. Augstburger will be responsible for coordinating the
Company's sales and marketing development in the European region.
Mr. Augstburger has held several management positions in companies operating
in the health sector. Just prior to joining Atrium, Mr. Augstburger was
General Manager of Arkopharma Canada. Previously, he also held executive
positions at various companies in the health sector, including the German
company Heel GmbH where he successively held the positions of Managing
Director of Heel's subsidiaries in Africa and the United States.
    Atrium also welcomes Mr. David Belaga to its sales and marketing team. He
will oversee commercial development in North America of the Mucos product
line, which includes Wobenzym(R) N, a well-known product currently sold in
Germany and some Eastern European countries. Mr. Belaga has 20 years
experience in sales and marketing within the health and wellness industry, in
which he also held key management responsibilities. Previously, he has worked
for companies such as Amerifit Nutrition and American Home Products (now
Wyeth), among others. During his career, he has successfully launched several
product brands, including Estroven, now one of the best selling nutritional
supplements in the American market.
    "These appointments will supply Atrium with the complementary resources
and expertise required to pursue the dynamic development of its two operating
platforms in Europe and United States that offer very high commercial
potential for the Company. Our development strategy is based on two main
pillars - sustained organic growth and acquisitions of financially strong
companies that market high quality products. Our recent acquisition of
Multicare B.V., as well as Mucos Emulsions GmbH last July, are examples of
this strategy in action. There is also a great deal of development potential
in our current and new product lines, notably Wobenzym(R) N for which we are
just starting to implement our focused marketing plan in the United States,"
said Mr. Serge Yelle, Atrium's Executive Vice President - Health and Nutrition
Division.

    About Atrium

    Atrium Innovations Inc. is a recognized leading developer, manufacturer
and marketer of science-based products for the cosmetics, pharmaceutical,
chemical and nutrition industries. The Company focuses primarily on growing
segments of the health and personal care markets which are benefiting from the
trends towards healthy living and the ageing of the population. Atrium markets
a broad portfolio of active ingredients, specialty chemicals and health and
nutrition finished products through its highly specialized sales and marketing
network in more than 50 countries, primarily in North America, Europe and
Asia. Atrium has over 700 employees and operates five manufacturing
facilities. Additional information about Atrium is available on its Web site
at www.atrium-innov.com.

    Cautionary Note and Forward-Looking Statements

    This press release contains certain forward-looking statements with
respect to the Company. These forward-looking statements, by their nature,
necessarily involve risks and uncertainties that could cause actual results to
differ materially from those contemplated by these forward-looking statements.
The Company considers the assumptions on which these forward-looking
statements are based to be reasonable, but cautions the reader that these
assumptions regarding future events, many of which are beyond its control, may
ultimately prove to be incorrect since they are subject to risks and
uncertainties that affect the Company. For additional information with respect
to these and other factors, see the Company's quarterly and annual filings
with the Canadian securities commissions. The Company disclaims any intention
or obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, other than as required
by law.




For further information:

For further information: Investor Relations: Pierre Fitzgibbon,
President and Chief Executive Officer, (418) 652-1116,
pfitzgibbon@atrium-innov.com; Media Relations: Frédéric Tremblay, HKDP, (514)
395-0375, ext. 234, ftremblay@hkdp.qc.ca

Organization Profile

Atrium Innovations Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890